• Truist analyst Joon Lee has initiated coverage of Cyclerion Therapeutics Inc (NASDAQ: CYCN) with a Buy rating and price target of $14, suggesting a massive 374% upside.

• The development of drugs targeting the brain's nitric oxide (NO) system is "ripe for therapeutic intervention," the analyst tells investors.

• Lee contends that Cyclerion's lead drug, CY6463, can successfully enhance the NO signaling in the brain.

• Lee adds that CY6463 is currently in three signal finding clinical studies - MELAS, Alzheimer's disease with vascular dementia, and cognitive impairment associated with schizophrenia - with data from these trials expected throughout 2022.

• Last month, Cyclerion announced a publication showing that the administration of a small molecule soluble guanylate cyclase (sGC) stimulator reduced markers associated with neuroinflammation in preclinical models.

• These data suggest that CNS penetrant sGC stimulators, such as CY6463 and CY3018, could provide therapeutic benefits.

• Price Action: CYCN shares closed higher by 10.90% at $2.95 on Wednesday.

Latest Ratings for CYCN

View More Analyst Ratings for CYCN
View the Latest Analyst Ratings

See more from Benzinga

• Click here for options trades from Benzinga

• Healthcare Services Stock Falls After Q3 Earnings Miss, Warns On Challenging Environment

• Why Are LumiraDx Shares Trading Higher Today?

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.